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Transcriptional Regulation 
and Epigenetics in 
Cardiovascular Cells: Role of the 
Mineralocorticoid Receptor
Lisa Deng, Lutz Hein and Achim Lother
Abstract
The mineralocorticoid receptor (MR), a ligand-activated transcription factor, 
plays an important role in the pathophysiology of cardiovascular disease. Epigenetic 
mechanisms such as DNA methylation or histone modifications in addition to the 
DNA sequence are decisive regulators of cell type-specific transcriptional activ-
ity and gene expression by controlling chromatin accessibility. In this review, we 
summarise the current knowledge about the impact of MR on gene expression in 
cardiovascular cells. We discuss studies investigating the interaction of MR with 
epigenetic mechanisms or other transcription factors and their implications for the 
cardiovascular system. Finally, we compare mechanisms of transcriptional regula-
tion by MR and other nuclear transcription factors. In conclusion, MR is an impor-
tant regulator of gene expression in cardiovascular cells. Potential mechanisms of 
cell type-specific transcriptional regulation by MR include interaction with other 
transcription factors or co-regulators, tethering and post-translational modifica-
tions of the MR. Further studies will be needed to clarify the interplay of MR and 
epigenetic mechanisms.
Keywords: mineralocorticoid receptor, epigenetics, chromatin, gene expression,  
cell types
1. Introduction
Mineralocorticoid receptor (MR) antagonists are a cornerstone in the current 
pharmacological therapy of chronic heart failure [1, 2]. MR in renal epithelial cells 
plays an important role for ion homeostasis and blood pressure control, but MR is 
also expressed in extrarenal tissue including different cell types of the heart and the 
vasculature [3]. This understanding has subsequently triggered intense research 
on the molecular basis of MR activity in the cardiovascular system. The MR is a 
member of the nuclear receptor (NR) family, which consists of different DNA-
binding transcription factors [4]. As a ligand-activated transcription factor, MR 
controls the expression of its target genes. Despite increasing evidence for rapid, 
non-genomic effects of MR, regulation of gene expression is still regarded as a key 
feature of MR action. The MR holds a unique position among steroid-activated 
nuclear receptors as it binds two ligands, aldosterone as the main ligand as well 
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as cortisol (corticosterone in rodents) with similar affinity. Indeed, progesterone 
which acts as an antagonist at the human MR [5] and, according to recent studies, 
has also activating properties at chicken and zebrafish MR [6] could also be seen 
as a third ligand to the MR. Despite their diverse range of action, nuclear receptors 
share a common, highly conserved structure [7]. A ligand-induced conformational 
change of the ligand-binding domain (LDB) leads to the activation of the receptor. 
Upon translocation into the nucleus, NR modulates transcription by interacting 
with specific DNA sequences. Eukaryote DNA is not linear but wrapped up in a 
complex with histones forming the chromatin. Histones are subjected to a variety of 
reversible post-translational modifications, which, in turn, can change chromatin 
density, accessibility and high-order chromatin structure and thereby determine 
transcription factor binding and gene expression [8].
Epigenetics is an emerging topic in cardiovascular research. The heart and 
the vasculature are composed of numerous different cell types including cardiac 
myocytes, endothelial cells, vascular smooth muscle cells, fibroblasts, immune 
cells and others [9]. These different cell types show marked heterogeneity in their 
specific transcriptomes [10–13]. Transcriptome analyses of different cell types of 
the heart revealed transcriptional changes during development and disease [12, 
13], and these changes were associated with distinct alterations in the epigenome. 
For example, dysregulation of histone modifications or DNA methylation has been 
linked to numerous diseases of the cardiovascular system, such as atherosclerosis 
[14–16], hypertension [17, 18] or heart failure [19–22]. Based on these findings 
pharmacological targeting of epigenetic modifiers has been proposed for treatment 
of cardiovascular disease and successfully tested in preclinical models [23, 24].
Epigenetic modifications, such as histone modifications or DNA methylation, 
have been identified as decisive regulators of transcription factor activity, as chro-
matin compaction determines the cell-specific accessibility of DNA [4]. Vice versa, 
NR can alter the chromatin structure through recruitment of cofactors, which act 
as chromatin remodelers [25]. Chromatin immunoprecipitation (ChIP) assays with 
subsequent deep sequencing represent a powerful technique for genome-wide anal-
ysis of histone modifications or other DNA-associated proteins [26]. The combina-
tion of different histone modifications, often referred to as the histone code, gives 
information on proximal and distal regulatory DNA elements, including promoters 
and enhancers. Promoters are often located in close proximity to the transcrip-
tion start site (TSS) and associated with monomethylation of histone 3 at lysin 4 
(H3K4me1), while enhancers are usually distal to TSS and marked by trimethylation 
of H3K4 (H3K4me3). Active promoter or enhancer sites are marked by acetylation 
of histone 3 at lysin 27 (H3K27ac); in contrast, H3K9me3 and H3K27me3 mark 
heterochromatic or repressed regions [27]. Epigenetic modifications are reversible, 
being recognised, established or removed by reader, writer and eraser proteins. For 
example, acetylation of histones is regulated by two counteracting enzymes which 
add (histone acetyltransferases, HAT) acetyl groups to lysine residues or remove 
them (histone deacetylases HDAC) [28].
DNA methylation of CpGs is the only known epigenetic mechanism directly 
targeting the DNA and plays an important role in gene silencing when being 
recognised by reader proteins such as methyl-CpG-binding protein 2 (MeCP2) 
that act as transcriptional repressors [29]. DNA methylation is established and 
maintained during mitosis by DNA methyltransferases (DNMT) [29]. Oxidation of 
methylcytosines to hydroxylmethylcytosines, which is an intermediate step towards 
demethylation, is mediated by members of the ten-eleven translocation (TET) 
enzyme family. This occurs predominantly in promoter and enhancer regions with 
low CpG density, resulting in low methylated regions and can be used to identify 
active regulatory regions [29, 30]. CpG-rich regions, also referred to as CpG islands, 
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in the promoter of constitutively active genes are typically unmethylated [29]. This 
allows to use DNA methylation as a stable mark of cell lineage during development 
[31]. Analysis of the DNA methylome of murine cardiomyocytes revealed distinct 
DNA methylation pattern during cardiomyocyte development and disease [32]. 
Demethylation of cardiac gene bodies correlated with active histone marks and 
increased gene expression. Interestingly, by comparison of the DNA methylome of 
healthy and failing cardiomyocytes, the DNA methylation pattern of failing car-
diomyocytes was bearing a partial resemblance to foetal cardiomyocytes; however, 
changes were not major [32]. A similar result could be observed in human failing 
cardiac myocytes. Pathological gene expression in heart failure was accompanied by 
changes in active histone marks, whereas the DNA methylation pattern remained 
mostly the same [33]. Similarly, changes in the transcriptome of cardiac myocytes 
following myocardial infarction were accompanied by altered accessibility of 
chromatin [12].
Given the important role of epigenetics in transcriptional regulation, interaction 
of MR with epigenetic modifications; with epigenetic reader, writer or eraser pro-
teins; or with other transcription factors might control the cell type-specific impact 
of MR on gene expression and function. In this review article, we will summarise 
what is known about MR-dependent gene expression, epigenetic mechanisms and 
their interaction with MR in cardiovascular cells.
2.  Impact of aldosterone and MR on gene expression in the 
cardiovascular system
A series of experimental studies during the past years revealed distinct MR 
functions in cardiac myocytes, fibroblasts, endothelial cells, vascular smooth 
muscle cells and immune cells [3, 34, 35]. These studies provided evidence that 
the beneficial effect of MR antagonists in heart failure is directly related to MR 
in cardiovascular cells and independent from MR in renal epithelial cells. Several 
attempts have been made to understand the downstream signalling events following 
MR activation and to identify direct MR target genes in different cells or tissues of 
the cardiovascular system.
Early studies on cultured fibroblasts revealed an upregulation of collagen by 
aldosterone [36, 37] and by this suggested MR-dependent gene expression in car-
diovascular cells. Later studies applied microarray or RNA-sequencing techniques 
to systematically detect MR-responsive genes. Similar to fibroblasts, aldosterone 
induced the expression of collagen types I and III in cultured smooth muscle cells 
from the coronary artery [38]. In mouse aorta, aldosterone regulated the expression 
of genes related to vascular function, such as oxidative stress, extracellular matrix 
and angiogenesis [39]. Treatment of EAhy926 endothelial cells expressing MR after 
retroviral transfection with aldosterone leads to regulation of only 17 transcripts 
[40]. In contrast, 133 genes were found up- or downregulated by aldosterone in 
human umbilical vein endothelial cells with naïve MR expression but not after MR 
knockdown [41]. These genes were associated leukocyte migration and angiogen-
esis. Interestingly, aldosterone treatment had opposing effects on endothelial cell 
gene expression when compared to treatment with vascular endothelial cell growth 
factor, a potent pro-angiogenic factor [41].
In a H9C2 cardiac myocyte cell line stably expressing MR, 53 transcripts were 
detected to be differentially regulated after treatment with aldosterone, the major-
ity of them being upregulated [42]. Among the upregulated transcripts were genes 
related to extracellular matrix deposition such as Adamts1 (A disintegrin and metal-
loprotease with thrombospondin motifs), Pai-1 (plasminogen-activator inhibitor 1) 
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or Tnx (tenascin-X) [42]. Studies using selective MR or GR antagonists confirmed 
MR-dependent expression of these genes in H9C2 cells [43, 44]. In heart tissue 
from untreated mice overexpressing MR in cardiac myocytes, microarray analysis 
revealed 24 transcripts upregulated and 22 transcripts downregulated. Again, the 
expression of Adamts1 and Pai-1 was induced by MR overexpression [43]. Vice 
versa, MR deletion from cardiac myocytes leads to differential regulation of 158 
genes in heart tissue, including upregulation of Nppa (atrial natriuretic peptide 
type A); however, there was no clear reduction of genes related to collagen synthesis 
in this study [45]. In doxorubicin-treated mice, MR deletion from cardiac myocytes 
prevented the repressive effect of doxorubicin on gene expression, likely by a post-
transcriptional mechanism [46]. One well-investigated gene that is upregulated 
in heart tissue by cardiac myocyte MR overexpression or aldosterone treatment 
is neutrophil-gelatinase-associated lipocalin (Ngal) [47]. Interestingly, Ngal was 
upregulated by aldosterone in endothelial cells and vascular smooth muscle cells as 
well [47].
Taken together, there is an overlap of several genes that were similarly regulated 
by MR in different cardiovascular cells or tissues including Sgk1 [41–43, 45], Tsc22d3 
[40, 41], Adamts1 [41–43], Fkbp5 [40, 41, 43], Klf9 [39–41], Ngal [47] or Per1 [41, 
48, 49], indicating a common signature of MR-regulated genes. Interestingly, 
these genes are well-related to the pathophysiological impact of MR on fibrosis and 
inflammation in the cardiovascular system.
3. Regulation of MR transcriptional activity
Transcriptional activity of MR is regulated at different levels: ligand binding, 
nuclear translocation, chromatin state and MR-DNA interaction. The main focus 
of this article will be on chromatin state and MR-DNA interaction; however, some 
specificities of cardiovascular cell types should be noticed: First, as MR binds to 
aldosterone or glucocorticoids with similar affinity, different mechanisms exist that 
allow ligand-specificity of MR. One of them is co-expression of 11β-hydroxysteroid 
dehydrogenase type 2 (11βHSD2), an enzyme converting glucocorticoids to deri-
vates that are inactive at the MR (for review, see [50]). In the cardiovascular system, 
11βHSD2 is highly expressed in endothelial cells, low expressed in cardiac myocytes 
and smooth muscle cells and probably absent in immune cells [51]. Second, while 
in most cell types unliganded MR is predominantly located at the cytoplasm and 
shuttles into the nucleus upon ligand binding, MR has been described to be con-
stitutively located at the nucleus in cardiac myocytes [52]. Immunohistochemical 
analysis of heart tissue revealed nuclear localization of the MR, and subfractional 
analysis showed that the vast majority of MR was chromatin-bound irrespective of 
plasma aldosterone or glucocorticoid levels. The subcellular distribution depended 
on the balance of heat shock protein 90 expression and the synergy of two nuclear 
localization signals. Interestingly, transcriptional activation of chromatin-bound 
MR nevertheless required the presence of a ligand [52].
4. Validation of MR-responsive genes
To further elucidate the role of MR in transcriptional regulation, it has been 
aimed to identify genes that are direct MR targets by proofing MR binding to a 
corresponding regulatory region by ChIP experiments. In a human embryonic 
kidney cell line (HEK293) stably transfected with myc-tagged hMR, Cnksr3 was 
identified as a novel MR target gene containing MR binding sites (MBS) upstream 
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of the transcription start site using ChIP in conjunction with microarray analysis 
(ChIP-chip). Cnksr3 was described as highly expressed in response to aldosterone, 
mediating ENaC activity and thereby influencing transepithelial Na+ transport in 
renal collecting duct cells [53]. Ueda et al. combined ChIP with high-throughput 
sequencing for a genome-wide analysis of MR target genes in renal distal con-
voluted tubular cells and identified 1113 MR binding sites associated with 1414 
genes [54]. Combining data from a microarray study 186 genes were considered to 
be aldosterone-responsive, showing an increase in mRNA expression levels after 
aldosterone stimulation and a decrease in expression by inhibitory treatment with 
spironolactone. Interestingly, only 25 genes showed an overlap between both assays 
and were thus classified as MR target genes, among those the well-known target 
genes Sgk1, Fkbp5 and Tsc22d3 [54]. Of note, strong enrichment of MR does not 
necessarily translate into increased expression of target genes. In another study, 
analysis of renal MR target genes revealed four commonly acknowledged target of 
MR signalling in renal cells such as Scnn1a, Fkbp5, Zbtb16 and Per1 and nine other 
genes not associated with MR signalling before [55]. MR target genes could be 
subcategorized according to their different kinetics of MR-dependent activation 
of gene expression into early, intermediate and late response genes [55]. However, 
molecular mechanisms of MR signalling are highly cell-specific, as distinct target 
genes could be found in one experiment but not reproduced in another [54, 55], 
whereas other MR target genes seem to be independent from tissue or cell type such 
as Fkbp5 or Per1 [54–57].
MR binding sites seem to be widespread across the genome, an equal propor-
tion (almost 40%) of all identified peaks were located either within introns or 
intergenic. Surprisingly, only 40 of all approximately 1000 MBS were found within 
promoter regions and 11% within enhancer regions [55]. Among the 13 genes corre-
lating to the highest MR binding peak scores in human renal cells, LINC00963 was 
not regulated by MR, despite high aldosterone-induced MR recruitment. As the MR 
binding site was located far from the nearest TSS, the involvement of this remote 
MBS in transcriptional regulation of another gene through long-range chromatin 
interactions is possible [55, 58].
For cardiovascular cells, available studies are restricted to MR binding in the 
promoter region of certain target genes. Cav1.2, a voltage-gated calcium channel, 
could be identified as an MR target in the cardiovascular system using mutational 
and in silico analysis. An aldosterone-dependent recruitment of MR to the alterna-
tive cardiac Cacna1c P1-promoter was observed, subsequently regulating expression 
of cardiac Cav1.2 transcripts in cardiac myocytes as well as in vascular smooth 
muscle cells, underlining the importance of aldosterone signalling in vascular reac-
tivity and regulation of blood pressure [59]. In a similar approach, MR-dependent 
regulation of Icam1 in cultured endothelial cells was demonstrated using a reporter 
assay with different promoter fragments [60].
5. Mineralocorticoid receptor response elements
The canonical GRE DNA motif consists of two inverted palindromic half sites, 
separated by a 3 bp spacer [AGAACAnnnTGTTCT (Figure 1)] [61]. Different varia-
tions of this motif exist in human renal cells with the bases C5 and G11 remaining 
essential for MR binding. Strong sequence degeneration of the classic consensus 
motif correlated with low MR enrichment and therefore disrupted MR interaction 
[55]. A small percentage of 7.4% MBS contained the classic consensus MRE motif; 
the larger part of all identified MRE consisted of half sites or a combination out 
of palindromic sequences and half-MREs [55]. Of note, not all MR binding sites 
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contain an MRE consensus motif. The majority of peaks lacked the MRE implying 
interaction of MR with the DNA directly by binding to specific DNA sequences 
different from the consensus motif, indirectly via protein–protein interactions or 
possibly through tethering as known for GR (Figure 1) [55, 62, 63]. Indeed, an 
aldosterone-dependent trans-activation of AP-1 could recently be proven in human 
cells, underlining this hypothesis [64]. Interestingly, all MBS in rat hippocampal 
tissue contained an MRE [57], suggesting that the mode of MR-DNA interaction 
might be cell- or tissue-specific.
When analysing MRE it has to be taken into account that MR and GR share a 
common consensus sequence. Both receptors are simultaneously expressed in vari-
ous tissues and interact with each other. For example, MR and GR are able to form 
homodimers as well as heterodimers in rat hippocampal tissue after acute stress 
challenges [56]. The binding of homodimers of the respective receptors or MR/GR 
heterodimers seems to be gene-specific. Using a tandem ChIP approach, it could be 
pointed out that MR and GR mainly bind as MR/MR and GR/GR homodimers at 
the GRE of Sgk1, whereas MR/GR heterodimer formation could be proven for the 
Figure 1. 
Proposed modes of MR-DNA interaction. Mineralocorticoid receptors can directly bind to MR response 
elements consisting of a 15 bp palindromic DNA sequence (A) or to composite elements when interacting 
with a neighbouring transcription factor (B). Indirect MR-DNA interaction can be facilitated by tethering to 
another transcription factor (C). MR-DNA interaction is modulated by co-regulatory transcription factors or 
post-translational modifications of the MR (D). MR, mineralocorticoid receptor; TF, transcription factor; CR, 
co-regulator; ac, acetylation; P, phosphorylation.
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Per1 GRE in addition to homodimers of both receptors. Notably, at the Fkbp5 GRE 
MR seems to bind only in a heterocomplex with GR [56], indicating distinct mecha-
nisms controlling binding of receptors to GRE, such as local chromatin accessibility 
or interactions with co-regulators [65]. Interactions of MR/GR heterodimers with 
the Per1 promoter in response to aldosterone or cortisol stimulation could also be 
detected in a human renal cell line [49]. In an extensive time-course ChIP-qPCR 
study, the authors provide evidence for different dynamics in MR or GR recruitment 
to the promoter region of a given target gene. MR recruitment kinetics onto the 
Per1 promoter was ligand-dependent. Aldosterone induces a distinct kinetic pattern 
differing from MR-GR recruitment kinetics [49], suggesting different dynamics as 
mechanisms for receptor selectivity. MR/GR heterodimer show distinct dissociating 
rates differing from MR/MR or GR/GR homodimers [66], resulting in a stronger 
GRE binding and a synergistic effect on controlling transcriptional activity of each 
receptor [49, 56]. However, contrasting results have been reported. MR/GR het-
erodimers either enhanced [56] or inhibited [67] transcription of given target genes 
when compared to respective homodimers. In cardiac myocytes, Per1 was upregu-
lated by both cortisol and aldosterone. The impact of aldosterone was enhanced in 
the presence of the CLOCK transcription factor, suggesting a cooperative effect of 
both transcription factors on Per1 expression [48]. Meinel et al. demonstrated an 
interaction of MR with the transcription factor specificity protein 1 (SP1) leading 
to the binding of an alternative MRE in the promoter region of epidermal growth 
factor receptor (EGFR) gene. The SP-1-dependent transactivation of EGFR through 
MR could also be demonstrated in cultured smooth vascular cells [68].
Comparison of GR-ChIP data with MR-ChIP data from rat hippocampal tissue 
revealed 918 MR-specific binding sites, 1450 GR-specific and 475 binding sites 
shared by MR and GR, all containing the GRE motif [57]. In all MR-exclusive 
binding sites, an additional motif, corresponding to the Atoh1 binding sequence, 
was present, and the protein was not expressed in hippocampal tissue. However, 
in Atoh1 belonging to the basic helix–loop–helix (bHLH) family of transcription 
factors, the brain-specific NeuroD family members could be identified as potential 
candidates for interaction with MR, thus ensuring MR specificity at MR-exclusive 
binding sites [57]. Different studies point at a role of differences in the nucleotide 
sequence of GREs in mediating distinct transcriptional activity of MR and GR 
[56, 59, 68], as some GRE do not enhance binding of the receptors [56], other GRE 
sequences favouring MR binding [69] or exclusively binding MR [68]. The ability 
to bind negative glucocorticoid response elements (nGRE) and therefore repress-
ing transcription of given target genes is restricted to GR signalling and not shared 
with other steroid receptors [70]. Despite having a common ancestral with the 
capacity of binding nGRE, the ability was lost in the MR due to different mutations 
at independent timepoints and enhanced in the GR lineage, resulting and contrib-
uting to the capability of MR and GR to show specific and distinct transcriptional 
signatures even though being highly homologous. Nevertheless, repressing effects 
on transcriptional activities are not unique for GR as MR are likewise able to 
trans-repress NFκB signalling through tethering effects without interfering with 
DNA binding of the complex, putting an interesting angle to the pro- and antiin-
flammatory effects of MR and GR. However, trans-repressing effects of MR are 
notably weaker than those of GR [64]. Of note, in addition to the beforementioned 
activating protein-protein interactions of MR on inflammatory AP-1 signalling, 
suppressing effects on AP-1 activities in a DNA-sequence-specific manner—and 
therefore target gene-specific—could also be elucidated, stressing out the necessity 
of identifying cell type-specific target genes of MR in order to dissect augmenting 
effects of MR from repressing effects for the development of potential new MR 
antagonists [64].
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
8
6. Co-regulators of MR activity
MR transcriptional activity in the nucleus is finely controlled by a variety of 
different mechanisms, including the recruitment of co-regulators, a heteroge-
neous group of non-receptor proteins (Figure 1) [71]. Co-regulators modulate 
the transcriptional activity of the receptor by either acting as coactivators or as 
corepressors [72]. They predominantly interact at specific regions in the NTD 
and at the LBD. The NTD represents the least conserved region across the steroid 
receptor family and thereby harbouring most potential for differential recruit-
ment of co-regulators [73]. The LDB is conserved between different species and 
harbours a ligand-dependent activation function site (AF-2), which is exposed 
upon conformational changes induced by ligand binding of the receptor [74]. AF-2 
as a docking platform is essential for co-regulator binding. Many co-regulator 
molecules interact via an LxxLL (L stands for a leucine, x for any other amino acid) 
motif with the AF-2 region [50], e.g. the first identified and well-characterised 
NR co-regulator steroid receptor coactivator-1 (SRC-1) [73]. Among the over 400 
putative co-regulators discovered in screening assays, a few MR-specific interac-
tion partners could be characterised such as the elongation factor eleven-nineteen 
lysine-rich leukaemia (ELL). ELL is able to differentially regulate MR and GR, 
selectively enhancing MR transcriptional activity and repressing GR-mediated 
transactivation [75]. GEMIN4 represents an MR corepressor, attenuating MR tran-
scriptional activity in a cell- and gene-specific manner, as a repressive effect could 
be demonstrated in human embryonic kidney cells but not in a rat cardiomyocyte 
cell line [76]. However, GEMIN4 actions are not restricted to MR, leaving NF-YC as 
the only described MR-specific corepressor [77]. Just recently, a specific MR cofac-
tor modulation has been proposed as a molecular mechanism for the differential 
antifibrotic properties of the novel nonsteroidal MR antagonist finerenone when 
compared to steroidal MR antagonists [78].
7. Post-translational modification of the MR
Post-translational modifications such as phosphorylation, ubiquitination, 
sumoylation or acetylation are described to influence MR transactivation [79]. 
Phosphorylation of MR has contrasting effects, as it has reported early that 
phosphorylation of MR is necessary for aldosterone binding and enhancing the 
DNA-binding ability of MR [80, 81]. On the other hand, phosphorylation of MR on 
serine and threonine residues mediated by cyclin-dependent kinase 5 (CDK5) was 
shown to attenuate MR transcriptional activity, whereas nuclear receptor accumu-
lation was not altered, suggesting impaired interaction of MR with co-regulators 
[82]. Recently, the ubiquitously expressed casein kinase 2 (CK2) was identified 
as a positive modulator of MR transcriptional activity by direct phosphorylation 
of the receptor and potentially by changing the phosphorylation status of other 
MR-co-regulators [83]. Interestingly, phosphorylation of MR is also implied as a cell 
type-specific mechanism, modulating MR activity. Hyperkalaemia was found to 
increase MR phosphorylation at S843 and subsequently prevent ligand-binding and 
receptor activation, a phosphorylation site specific in renal intercalated cells [84]. 
Intriguingly, the phosphorylation of MR can also regulate the ubiquitylation state 
and the subsequent degradation of the protein [85].
The epigenetic writer proteins HDACs are generally perceived as corepressors 
of nuclear receptors [86]. The attenuating effects on gene transcription of the 
earliest described corepressors, nuclear receptor corepressor (NCoR) and silencing 
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mediator of retinoid and thyroid receptor corepressor (SMRT) rely on the subse-
quent recruitment of HDACs [72]. Different studies could reveal that increased 
acetylation of MR, induced by HDAC inhibition, interferes with MR recruitment 
onto the DNA and attenuates transactivation of MR target genes [87, 88]. HDAC3 
is acting as a coactivator in this context, as deacetylation of MR in the hinge region 
restores transcriptional activities of the receptor [88]. The treatment with HDAC 
inhibitors has also been linked to reduced antifibrotic effects in DOCA-salt-induced 
hypertensive rats and decreased expression of inflammatory markers in spontane-
ously hypertensive rats [17, 88, 89].
8. Summary
In summary, the distinct biological effects of MR in different cardiovascular 
cells are associated with changes in gene expression. Epigenetic modifications and 
modifying enzymes have been identified as crucial regulators of gene expression 
and cellular function in the cardiovascular system; however, presently available 
data on MR-dependent gene expression in the cardiovascular system is predomi-
nantly derived from experiments on cultured cells, in some cases after artificial 
overexpression of the MR, or tissue analysis. Analyses of complex tissues consisting 
of a dynamically changing mixture of multiple cell types can lead to ambigu-
ous results. To date there is no ChIP-seq data published describing genome-wide 
MR-DNA interactions in cardiovascular cells. Studies in renal epithelial cells or 
brain tissue indicate that MR-DNA interaction can occur in promoter regions as well 
as at distal enhancer sites, but it remains speculative whether the insights from renal 
epithelial cells can be applied to the cardiovascular system as well.
This implies the necessity to perform cell type-specific studies from primary 
cardiovascular cells in homeostasis and different states of disease in order to 
identify distinct changes in gene expression and (epigenetic) mechanisms regulat-
ing MR activity in a given cell type (Figure 2). Utilisation of cell type-specific 
bulk or single-cell RNA-sequencing as well as integrated analysis of locus-specific 
histone modifications and DNA methylation, spatial organisation of the chromatin, 
MR-DNA binding and MR post-translational modification would allow a compre-
hensive insight into regulation of transcription by MR in cardiovascular cells and 
might lead to novel concepts for selective MR-targeting therapeutics.
Figure 2. 
Proposed epigenetic determents of MR transcriptional activity. Transcriptional activity of the 
mineralocorticoid receptor is determined by DNA methylation and histone modifications governing chromatin 
accessibility and activation status of promoter and distal enhancer regions. Transactivation of MR-bound 
promoter or enhancer regions involves spatial chromatin organisation and other transcription factors. MR, 
mineralocorticoid receptor; TF, transcription factor; ac, acetylation; me, methylation.
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